UBS Group
APLS

UBS Group’s Apellis Pharmaceuticals APLS Stock Holding History

UBS Group’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-15,500
Closed -$1.06M – 10700
2022
Q3 		$1.06M Buy
+15,500
New +$917K ﹤0.01% 3708
2020
Q1 		– Sell
-9,300
Closed -$285K – 7940
2019
Q4 		$285K Buy
+9,300
New +$257K ﹤0.01% 5330

Other funds holding APLS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

UBS Group's APLS Position: Q1 2026 in Review

UBS Group increased its Apellis Pharmaceuticals (APLS) stake by 48% in Q1 2026, buying an estimated $43.5M and bringing the position to 6,206,681 shares worth $250M. The position accounts for 0.04% of the portfolio, ranked #510.

UBS Group first reported a position in APLS in Q4 2017 and has held it in 34 quarters since. 321 funds tracked by Wall St. Rank hold APLS as of Q1 2026.

  • UBS Group held 6,206,681 shares of Apellis Pharmaceuticals worth $250M as of Q1 2026.
  • UBS Group bought 2,020,459 Apellis Pharmaceuticals shares in Q1 2026, an estimated $43.5M.
  • Apellis Pharmaceuticals made up 0.04% of UBS Group's portfolio in Q1 2026, its #510 holding.
  • UBS Group first reported a position in Apellis Pharmaceuticals in Q4 2017 and has held it in 34 quarters since.
  • 321 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.